Basic Neurosciences · Paper A
Serotonin synthesis
This pathway matters because blocking just its first step is enough to lower brain serotonin measurably within hours, showing the tryptophan-to-serotonin route is a real physiological lever and not just a textbook diagram. Serotonin is built from the dietary amino acid tryptophan in a short two-step pathway. A research volunteer given a tryptophan-free drink, e.g. one whose brain serotonin drops within hours and, if vulnerable to depression, whose mood transiently worsens, demonstrates the pathway's role directly. Identify tryptophan hydroxylase as the rate-limiting step before tracing later metabolites.
Tryptophan hydroxylase is the rate-limiting enzyme, converting tryptophan to 5-HTP (5-hydroxytryptophan, the direct serotonin precursor). Aromatic L-amino-acid decarboxylase then converts 5-HTP to serotonin itself. Serotonin is later broken down by MAOMonoamine oxidase, an enzyme that breaks down mood-related brain chemicals.Read more → (monoamine oxidase, an enzyme that breaks down transmitters) into 5-HIAA. In the pineal gland it is instead converted into melatonin. Raised 5-HIAA on a urine sample, e.g. found incidentally during a carcinoid work-up, reflects serotonin breakdown and turnover rather than an intermediate waiting to become serotonin. In practice, tryptophan depletion studies exploit exactly this pathway to test serotonin's causal role in mood experimentally.
It is easy to memorise that serotonin is a involved in mood, but the exam-relevant, clinically useful knowledge is the actual biochemical pathway: what it is made from, which enzyme controls the speed of production, and what happens to serotonin afterwards. This matters because the pathway is not just theoretical; it is directly exploited by researchers to test whether low serotonin actually causes low mood, and understanding it explains why diet, certain drugs, and even a rare tumour can all be linked back to this one route.
Serotonin (5-hydroxytryptamine, also written 5-HT) is synthesised from the dietary amino acid tryptophan (a building block of protein that the body cannot make itself and must obtain from food) in two enzymatic steps. The first and rate-limiting step, meaning the slowest step that sets the pace for the whole pathway, is catalysed by tryptophan hydroxylase, which converts tryptophan into 5-HTP (5-hydroxytryptophan, an intermediate compound with no major signalling role of its own). The second step is catalysed by aromatic L-amino-acid decarboxylase (AADC, an enzyme that removes a carboxyl group to activate several different monoamine transmitters), which converts 5-HTP into serotonin itself.
It is worth being precise here: once released and used as a signal, serotonin is broken down by (monoamine oxidase, an enzyme that metabolises monoamine transmitters including serotonin, dopamine, and noradrenaline) into 5-HIAA (5-hydroxyindoleacetic acid), a metabolite excreted in urine. A common trap is treating 5-HIAA as "serotonin waiting to happen"; in fact it is the opposite, a dead-end breakdown product that reflects increased serotonin turnover in the past, not increased production going forward. Separately, in the pineal gland specifically, serotonin follows a different fate: rather than being broken down, it is converted into melatonin, the hormone that governs the sleep-wake cycle, which is one reason drugs can sometimes affect sleep architecture as a side effect.
Because tryptophan hydroxylase is rate-limiting, blocking or depleting it has an outsized effect: reducing its activity or removing dietary tryptophan lowers brain serotonin levels within hours, far faster than you might expect from a two-step pathway. This single fact, that the whole pathway's speed is set by one enzyme working on one raw material, is what makes tryptophan depletion such a clean experimental tool.
Consider a research volunteer taking part in a classic tryptophan depletion study. They are given a special amino-acid drink deliberately free of tryptophan; within a few hours, their brain serotonin synthesis drops sharply because the raw material for the rate-limiting step has been removed. In healthy volunteers with no history of depression, this drop in serotonin usually produces little noticeable change in mood. But in people vulnerable to depression, for example those with a personal or family history, or those currently in remission from a depressive episode, this same tryptophan depletion can transiently worsen mood or even provoke a brief return of depressive symptoms. This experiment is a direct, elegant demonstration that lowering serotonin synthesis through this exact pathway has a measurable effect on mood in a susceptible population.
Serotonin synthesis is easily muddled with catecholamine synthesis (the pathway that makes dopamine and noradrenaline), because both pathways share AADC as a step. The two pathways start from different raw materials, however: catecholamine synthesis begins with tyrosine and its own rate-limiting enzyme, tyrosine hydroxylase, while serotonin synthesis begins with tryptophan and tryptophan hydroxylase. A question describing AADC as "the" rate-limiting enzyme for serotonin is testing exactly this confusion; AADC is shared and rarely the bottleneck for either pathway. Raised 5-HIAA should also not be confused with raised serotonin itself, since one measures past breakdown and the other measures current signalling activity.
There is no everyday clinical test of "serotonin synthesis" in a psychiatric patient, but the pathway is measured directly in specific, well-defined circumstances. In research, tryptophan depletion paradigms and, less commonly, direct assay of pathway metabolites are used to probe function. In clinical medicine, raised urinary 5-HIAA is a recognised marker used in the investigation of carcinoid syndrome, a condition caused by a serotonin-secreting neuroendocrine tumour, where the excess serotonin produced by the tumour is broken down and shows up as elevated 5-HIAA on a 24-hour urine collection.
The pathway is applied clinically in two quite different directions. First, most antidepressants that raise synaptic serotonin, such as SSRIs (selective serotonin reuptake inhibitors), act downstream of synthesis, by blocking reuptake of serotonin that has already been made, rather than by boosting tryptophan hydroxylase activity; understanding the synthesis pathway explains why increasing dietary tryptophan alone is not an established treatment for depression, even though depleting it can worsen mood in vulnerable people. Second, where the pathway is pathologically overactive, as in carcinoid syndrome, management is directed at the tumour and its hormonal output, typically with somatostatin analogues to control symptoms alongside definitive treatment of the tumour itself, guided by oncology and endocrinology teams rather than psychiatric prescribing. Source-wise, this biochemical pathway is anchored in NCBI Bookshelf/NIH neurochemistry descriptions of tryptophan hydroxylase as the rate-limiting synthesis step; it is not a NICE standalone psychiatric treatment pathway.
Remember the direction of the pathway precisely: tryptophan leads to 5-HTP leads to serotonin, and only afterwards does serotonin lead to 5-HIAA (breakdown) or, in the pineal gland, to melatonin (a separate downstream product, not a step on the way back to serotonin). A stem describing tryptophan hydroxylase as the rate-limiting enzyme is correct; a stem attributing that role to AADC is a classic distractor.
Serotonin synthesis runs from tryptophan, via the rate-limiting enzyme tryptophan hydroxylase, to 5-HTP, and then via AADC to serotonin itself, which is later broken down by into 5-HIAA (a carcinoid marker) or converted in the pineal gland into melatonin, and tryptophan depletion studies exploit this exact route to demonstrate serotonin's causal role in mood.